Výsledky vyhledávání - "M I Vera-Mendoza"

P533 Adalimumab 80mg every other week in inflammatory bowel disease: Treatment intensification outcomes in real life clinical practice

Autor: Y. Gonzalez Lama, I Omella Usieto, V Matallana Royo, P Bella del Castillo, I. El Hajra Martinez, M I Vera Mendoza, E. Santos Perez, R De Lucas Téllez de Meneses, B Menchen Viso, B. Ruiz Antoran, M I Calvo Moya, M González Rodriguez, I Gonzalez Partida

Publikováno v: Journal of Crohn's and Colitis. 15:S507-S509

Background Adalimumab (ADA) intensification is recommended for inadequate or loss of response in inflammatory bowel disease (IBD) patients. A new presentation of ADA 80mg administered every other week (eow) has been approved as an alternative to ADA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::af1ff9e265f5de7c11bb9147e3078299
https://doi.org/10.1093/ecco-jcc/jjab076.655

Zobrazit plný text záznamu

Effect of faecal microbiota transplantation on recurrent urinary tract infection in a patient with long-term suprapubic urinary catheter

Autor: E Múñez-Rubio, C Ferre-Aracil, A Valencia-Alijo, Antonio Ramos-Martínez, M I Vera-Mendoza, R Martínez-Ruiz

Publikováno v: Journal of Hospital Infection. 105:332-333

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::edafc6791dbc307d545ddae18cdb07e5
https://doi.org/10.1016/j.jhin.2020.01.016

Zobrazit plný text záznamu

P545 Deep remission assessed by endoscopy, magnetic resonance or intestinal ultrasound, in refractory Crohn’s disease patients in clinical remission with ustekinumab: a real-life single-centre experience

Autor: P Bella del Castillo, Y. Gonzalez Lama, M I Vera Mendoza, R De Lucas Téllez de Meneses, V Matallana Royo, B Menchen Viso, I Gonzalez Partida, I Omella Usieto, M I Calvo Moya, M González Rodriguez

Publikováno v: Journal of Crohn's and Colitis. 14:S464-S465

Background Current therapeutic goals in Crohn’s disease (CD) include not only the mere absence of symptoms but also the objective resolution of macroscopic lesions, so-called deep remission (DR), which has been related to better outcomes. DR is usu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d4062b696f076332b07b5681da52c574
https://doi.org/10.1093/ecco-jcc/jjz203.673

Zobrazit plný text záznamu

P378 Mucosal healing is achieved in most of the inflammatory bowel disease patients in clinical remission with vedolizumab: a real-life single-centre experience

Autor: V Matallana Royo, M González Rodriguez, Y. Gonzalez Lama, M Manso Manrique, I Omella Usieto, M I Vera Mendoza, I Gonzalez Partida, M I Calvo Moya, B Menchen Viso, R De Lucas Téllez de Meneses, P Bella del Castillo

Publikováno v: Journal of Crohn's and Colitis. 14:S355-S355

Background Current therapeutic goals in inflammatory bowel disease (IBD) include not only the mere absence of symptoms but also the resolution of endoscopic lesions, so-called mucosal healing (MH), which has been related to better outcomes. Data rega

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0ba48f9e961cd3d6e45036b14c5717e
https://doi.org/10.1093/ecco-jcc/jjz203.507

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání